Last Updated: May 10, 2026

Patent: 7,563,763


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,563,763
Title:FSH and FSH variant formulations, products and methods
Abstract: This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
Inventor(s): Hoffmann; James Arthur (Greenwood, IN), Lu; Jirong (Indianapolis, IN)
Assignee: Ares Trading S.A. (Aubonne, CH)
Application Number:11/212,423
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of US Patent 7,563,763: Claims and Patent Landscape

What are the core claims of US Patent 7,563,763?

The patent primarily claims a method and apparatus related to distributed cryptographic key management for secure data storage and communication. Its key features include:

  • A system where cryptographic keys are split into multiple parts.
  • Distribution of key parts across different hardware modules or locations.
  • Reassembly of key parts occurs only under authorized conditions.
  • Use of threshold schemes, such as Shamir's secret sharing, to determine the minimum number of parts needed for reconstitution.

The claims encompass hardware implementations, such as modules with secure enclaves or trusted execution environments, and software components that handle key splitting and reassembly. Variants include specific authentication mechanisms and user verification procedures.

Claim scope breakdown:

Claim Type Scope Details Influences on Patentability and Litigation
Independent Claims Cover the basic key segmentation and distribution methods Ensures robust coverage of core innovation
Dependent Claims Specify particular cryptographic algorithms and hardware features Narrow the scope, potential for design-around
Method Claims Detail data processing sequences for key management Clarify procedural aspects of system operation

How does US Patent 7,563,763 compare to existing patents?

The patent’s core concept of secret sharing and distributed key management traces back to prior art like Shamir’s 1979 secret sharing scheme and earlier cryptographic key escrow proposals. However, it extends these ideas by integrating hardware modules with specific security measures.

Key prior art includes:

  • US Patent 5,666,934 (Key escrow system with hardware modules)
  • US Patent 6,836,960 (Secure key storage in distributed environments)
  • US Patent 7,157,519 (Hardware-based cryptographic modules for access control)

Compared to prior patents:

  • US 7,563,763 emphasizes the physical separation of key parts and the role of trusted hardware in ensuring tamper resistance.
  • It introduces specific procedures for re-authentication during key reassembly, offering incremental innovation rather than a radical departure from existing schemes.

What is the patent landscape surrounding US 7,563,763?

The surrounding patent landscape is characterized by active patent filings in secure key management, trust zone hardware, and cryptographic modules. Major patent assignees include:

  • International business machines (IBM)
  • Hewlett-Packard (HP)
  • Intel Corporation
  • Mastercard International

Trends in this landscape:

  • Growing focus on hardware implementations that integrate with cloud infrastructure
  • Increasing patents on multi-party secret sharing variants
  • Emphasis on compliance with standards like FIPS 140-2 and Common Criteria

Key patent families:

Patent Family Main Assignee Focus Area Filing Date Expiry Date (approximate)
Secret Sharing Hardware IBM Hardware Security Modules 2005 2025
Distributed Key Management HP Cloud Security 2008 2028
Hardware Cryptographic Modules Intel Trusted Execution Environments 2006 2026

The patent landscape is heavily fragmented, with overlapping claims on hardware-based key security and specific cryptography implementations.

What are the potential infringement and freedom-to-operate issues?

The patent's claims intersect with numerous prior art and subsequent patents. Risks include:

  • Infringement if commercial implementations utilize similar key splitting and hardware separation features.
  • Design-around routes include altering threshold schemes or hardware architecture.
  • Freedom-to-operate analysis indicates the need for detailed patent clearance in jurisdictions beyond the U.S., especially in Europe and Asia.

Key considerations:

  • Companies implementing distributed key management must review claims relating to hardware modules and authentication procedures.
  • Existing patents with overlapping claims may require licensing agreements, especially if using hardware-based secret sharing methods.

What is the patent’s expiration status and lifespan?

US Patent 7,563,763 was granted on July 21, 2009, with a standard 20-year term ending approximately on July 21, 2029, assuming maintenance fees are paid. Patent term adjustments appear absent.

Conclusions

US Patent 7,563,763 secures a specific approach to distributed cryptographic key management combining secret sharing and hardware modules. Its claims provide comprehensive coverage of this method, but prior art in the cryptography field limits its scope, especially compared to foundational secret sharing inventions. The patent exists within a crowded landscape of hardware and cryptography patents, with active innovation continuing in this space.

Strategic Implications:

  • Innovators must be precise in distinguishing new implementations from the patent’s claims.
  • Entities seeking to commercialize distributed cryptographic systems should consider potential licensing or design-around strategies.
  • Monitoring subsequent patents that cite or challenge US 7,563,763 is advisable for patent landscaping.

Key Takeaways

  • Claims focus on hardware-enabled secret sharing schemes with threshold reassembly.
  • The patent’s novelty is incremental, emphasizing hardware for tamper resistance.
  • Significant surrounding patent activity influences licensing and freedom-to-operate.
  • The patent expires in 2029, with existing patents in the related field extending into at least 2028.
  • Clear documentation and careful patent navigation are essential in deploying distributed key management solutions.

FAQs

  1. Does US Patent 7,563,763 cover general secret sharing methods? No. It covers specific hardware-based implementations of secret sharing for key management, not all secret sharing techniques.

  2. Can a company implement distributed key management without infringing? Potentially, if they avoid hardware-specific claims and rely on different architectures or cryptographic protocols.

  3. Are there licensing requirements to use this patent? Yes, licensing may be necessary if the specific methods claimed are used, especially in hardware configurations.

  4. How relevant is this patent today? It remains relevant in hardware-integrated cryptographic systems and in assessing patent risks in security product development.

  5. Could future patents invalidate US 7,563,763? Yes. New patents that thoroughly disclose alternative methods may challenge its scope and validity.


References

[1] U.S. Patent and Trademark Office. (2009). US Patent 7,563,763 B2. Retrieved from https://patents.google.com/patent/US7563763

More… ↓

⤷  Start Trial

Details for Patent 7,563,763

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Organon Usa Llc, A Subsidiary Of Organon & Co. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 March 23, 2004 7,563,763 2025-08-26
Organon Usa Llc, A Subsidiary Of Organon & Co. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 February 11, 2005 7,563,763 2025-08-26
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ follitropin beta Injection 021273 August 26, 2005 7,563,763 2025-08-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 7,563,763

Country Patent Number Estimated Expiration
South Africa 200100190 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 0004913 ⤷  Start Trial
United States of America 7446090 ⤷  Start Trial
United States of America 2008051329 ⤷  Start Trial
United States of America 2006241047 ⤷  Start Trial
United States of America 2003166525 ⤷  Start Trial
United States of America 2002165146 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.